
Eli Lilly $3.8B Vaccine Acquisitions: Infectious Disease R&D
Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Analyze the application of generative AI in antibiotic discovery. This report examines the Phare Bio-Basilea partnership and Gram-negative drug development.
© 2026 IntuitionLabs. All rights reserved.